share_log
Reuters ·  Apr 2 11:30
Biogen’s Investigational Tau-Targeting Therapy Biib080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 282

Recommended

Write a comment